Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: A retrospective claims analysis

BMC Health Services Research

Volumn 14, Issue 1, 2014, Pages

  Abudagga, Azza ^a   Stephenson, Judith J ^a   Fu, An Chen ^a   Kwong, Winghan Jacqueline ^b   Tan, Hiangkiat ^a   Weintraub, William S ^c  

^a HEALTHCORE INC   (United States)

^b DAIICHI SANKYO INC   (United States)

^c CHRISTIANA CARE HEALTH SYSTEM   (United States)

Author keywords

Dabigatran; Healthcare; Non valvular atrial fibrillation; Oral anticoagulation; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DABIGATRAN; WARFARIN;

ADOLESCENT; ADULT; AGED; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; CLINICAL PRACTICE; COMORBIDITY; FEMALE; HUMAN; INSURANCE; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; RISK; STATISTICS AND NUMERICAL DATA; STROKE; UNITED STATES; VERY ELDERLY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COMORBIDITY; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; RISK; STROKE; UNITED STATES; WARFARIN;

EID: 84904270720     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-14-310     Document Type: Article

References (39)

1. Eliquis [package insert] http://packageinserts.bms.com/pi/pi-eliquis.pdf
2. Pradaxa [package insert] http://bidocs.boehringer-ingelheim.com/ BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/ Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf
3. Xarelto [package insert] http://www.xareltohcp.com/sites/default/files/ pdf/xarelto-0.pdf#zoom=100
4. Dabigatran versus warfarin in patients with atrial fibrillation. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Deiner H, Joyner CD, Wallentin L, and the RE-LY Steering Committee and Investigators, N Engl J Med 2009 361 1139 1151 10.1056/NEJMoa0905561 19717844
5. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, and the ROCKET AF Steering Committee for the ROCKET AF Investigators, N Engl J Med 2011 365 883 891 10.1056/NEJMoa1009638 21830957
6. Apixaban versus warfarin in patients with atrial fibrillation. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FWA, Zhu J, Wallentin L for the ARISTOTLE Committees and Investigators, N Engl J Med 2011 365 981 992 10.1056/NEJMoa1107039 21870978
7. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ, Chest 2012 141 Suppl 2 7S 47S 22315257
8. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY, Am J Med 2010 123 638 645 e4 10.1016/j.amjmed.2009.11.025 20609686
9. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Reynolds MR, Shah J, Essebag V, Olshansky B, Friedman PA, Hadjis T, Lemery R, Bahnson TD, Cannom DS, Josephson ME, Zimetbaum P, Am J Cardiol 2006 97 538 543 10.1016/j.amjcard.2005.09.086 16461052 (Pubitemid 43190046)
10. Racial and insurance disparities in hospital mortality for children undergoing congenital heart surgery. Chan T, Pinto NM, Bratton SL, Pediatr Cardiol 2012 33 1026 1039 10.1007/s00246-012-0221-z 22349675
11. Utilization of preventive care services and their effect on cardiovascular outcomes in the United States. Vaidya V, Partha G, Howe J, Risk Manag Healthc Policy 2011 4 1 7 22312222
12. Racial and ethnic disparities in the use of cardiovascular procedures: associations with type of health insurance. Carlisle DM, Leake BD, Shapiro MF, Am J Public Health 1997 87 263 267 10.2105/AJPH.87.2.263 9103107 (Pubitemid 27120564)
13. Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared with other specialists. Jong P, Gong Y, Liu PP, Austin PC, Lee DS, Tu JV, Circulation 2003 108 184 191 10.1161/01.CIR.0000080290.39027.48 12821540 (Pubitemid 36871301)
14. Specialty-related differences in the epidemiology, clinical profile, management and outcome of patients hospitalized for heart failure; the OSCUR study. Bellotti P, Badano LP, Acquarone N, Griffo R, Lo Pinto G, Maggioni AP, Mattiauda C, Menardo G, Mombelloni P, Eur Heart J 2001 22 596 604 10.1053/euhj.2000.2362 11259147 (Pubitemid 32625249)
15. Cardiology or primary care for heart failure in the community setting: process of care and clinical outcomes. Philbin EF, Weil HF, Erb TA, Jenkins PL, Chest 1999 116 346 354 10.1378/chest.116.2.346 10453861 (Pubitemid 29382117)
16. Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation. Huang C, Siu M, Vu L, Wong S, Shin J, J Eval Clin Pract 2012 Epub ahead of print
17. Comorbidity measures for use with administrative data. Elixhauser A, Steiner C, Harris DR, Coffey RM, Med Care 1998 36 8 27 10.1097/00005650- 199801000-00004 9431328 (Pubitemid 128456396)
18. The estimation power of alternative comorbidity indices. Baser O, Palmer L, Stephenson JJ, Value Health 2008 11 946 955 10.1111/j.1524-4733.2008.00343.x 18489502
19. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ, JAMA 2001 285 22 2864 2870 Epub 2001/06/13. DOI 10.1001/jama.285.22.2864 11401607 (Pubitemid 32537350)
20. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE, J Am Coll Cardiol 2011 58 395 401 10.1016/j.jacc.2011.03.031 21757117
21. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Cohen N, Almoznino-Sarafian D, Alon I, Gorelik O, Koopfer M, Chachashvily S, Shteinshnaider M, Litvinjuk V, Modai D, Stroke 2000 31 1217 1222 10.1161/01.STR.31.6.1217 10835435 (Pubitemid 30351236)
22. Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? Beyth RJ, Antani MR, Covinsky KE, Miller DG, Chren NM, Quinn LM, Landefeld CS, J Gen Intern Med 1996 11 721 728 10.1007/BF02598985 9016418 (Pubitemid 27009650)
23. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Radford MJ, Stroke 2000 31 822 827 10.1161/01.STR.31.4.822 10753982 (Pubitemid 30198422)
24. Bleeding risk with dabigatran in the frail elderly. Harper P, Young L, Merriman E, N Engl J Med 2012 366 864 866 10.1056/NEJMc1112874 22375994
25. The use of dabigatran in elderly patients. Legrand M, Mateo J, Aribaud A, Ginisty S, Eftekhari P, Huy PT, Drouet L, Payen D, Arch Intern Med 2011 171 1285 1286 10.1001/archinternmed.2011.314 21788545
26. Wood S, Deaths prompt dabigatran safety advisory in Japan Heartwire 2011 http://www.theheart.org/article/1264365.do
27. Hughes S, Dabigatran: Australia issues bleeding warning Heartwire 2011 http://www.theheart.org/article/1291757.do
28. U.S. Food and Drug Adminstration: Pradaxa (dabigatran etexilate mesylate), Drug Safety Communication-Safety Review of Post-Market Reports of Serious Bleeding Events 2012 http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820.htm
29. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S, Circulation 2011 123 2363 2372 10.1161/CIRCULATIONAHA.110. 004747 21576658
30. Adoption of new drugs by physicians: a survival analysis. Garjón FJ, Azparren A, Vergara I, Azaola B, Loayssa JR, BMC Health Serv Res 2012 12 56 10.1186/1472-6963-12-56 22401169
31. Is new drug prescribing in primary care specialist induced? Florentinus SR, Heerdink ER, van Dijk L, Griens AM, Groenewegen PP, Leufkens HG, BMC Health Serv Res 2009 9 6 doi:10.1186/1472-6963-9-6 10.1186/1472-6963-9-6 19134223
32. The Kaiser Family Foundation and Health Research & Education Trust, Employer Health Benefits 2010 Annual Survey http://ehbs.kff.org/pdf/2010/8085. pdf
33. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Roblin DW, Platt R, Goodman MJ, Hsu J, Nelson WW, Smith DH, Andrade SE, Soumerai SB, Med Care 2005 43 951 959 10.1097/01.mlr.0000178216.23514.b7 16166864 (Pubitemid 41442460)
34. Pharmacy benefits and the use of drugs by the chronically ill. Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, Laouri M, Landsman PB, Teutsch SM, JAMA 2004 291 2344 2350 10.1001/jama.291.19.2344 15150206 (Pubitemid 38656301)
35. Impact of 3-tier formularies on drug treatment of attention-deficit/ hyperactivity disorder in children. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Muriel AC, Frank RG, Arch Gen Psychiatry 2005 62 435 441 10.1001/archpsyc.62.4.435 15809411 (Pubitemid 40471693)
36. Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European heart rhythm association [EHRA], endorsed by the European society of cardiology [ESC] working group on thrombosis. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marin F, Palareti G, Kirchhof P, Thromb Haemost 2011 106 997 1011 10.1160/TH11-10-0690 22048796
37. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. MacLean S, Mulla S, Akl EA, Jankowski M, Vandvik PO, Ebrahim S, McLeod S, Bhatnagar N, Guyatt GH, Chest 2012 141 Suppl 2 1S e23S 22315262
38. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. Devereaux PJ, Anderson DR, Gardner MJ, Putnam W, Flowerdew GJ, Brownell BF, Nagpal S, Cox JL, BMJ 2001 323 1218 1222 10.1136/bmj.323.7323.1218 11719412
39. Preference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision making. Man-Son-Hing M, Gage BF, Montgomery AA, Howitt A, Thomson R, Devereaux PJ, Protheroe J, Fahey T, Armstrong D, Laupacis A, Med Decis Making 2005 25 548 559 10.1177/0272989X05280558 16160210 (Pubitemid 41384068)